Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Open Surgery Clear all
Terminated Phase 2 Interventional Results available

Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer

NCT00063258
View directory record Official record
Conditions
Lung Cancer
Interventions
Tarceva (OSI-774), Paclitaxel, Carboplatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2016 · Synced Jul 22, 2026, 2:08 PM EDT
Completed Not applicable Interventional Results available

Comparison of Vital HEAT (vH2) Temperature Management System to Upper-body Forced-air Warming

NCT00815191
View directory record Official record
Conditions
Surgery
Interventions
a forced-air warming cover, vital HEAT (vH2) Temperature Management System
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 17, 2016 · Synced Jul 22, 2026, 2:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of EXPAREL in Comparison to Standard of Care for the Treatment of Post Operative Dental Implant Pain

NCT02533440
View directory record Official record
Conditions
Postoperative Pain
Interventions
EXPAREL and Local Anesthetics, Oral Opioid and Local Anesthetics
Procedure
Lead sponsor
Bellaire Facial Surgery Center
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
Atlanta, Georgia • Houston, Texas • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2016 · Synced Jul 22, 2026, 2:08 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)

NCT07477418
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC), Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms
Interventions
Gemcitabine Delivered by Transarterial Microperfusion
Combination Product
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Jul 22, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Trabecular Micro-bypass Stent in Combination With Cataract Surgery in Subjects With Open Angle Glaucoma

NCT00323284
View directory record Official record
Conditions
Open-Angle Glaucoma
Interventions
iStent plus Cataract Surgery, Cataract surgery only
Device · Procedure
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
31
States / cities
Beverly Hills, California • Petaluma, California • Sacramento, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Jul 22, 2026, 2:08 PM EDT
Recruiting No phase listed Observational

Efficacy of Surgical Systems in Combination With Phacoemulsification: a Retrospective Analysis

NCT06953349
View directory record Official record
Conditions
Open-Angle Glaucoma
Interventions
Real-World efficacy of Hydrus Microstent with OMNI Surgical System in combination with Phacoemulsification: a retrospective analysis
Procedure
Lead sponsor
Barnet Dulaney Perkins Eye Centers
Network
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Jul 22, 2026, 2:08 PM EDT
Active, not recruiting Not applicable Interventional

Randomized Trial of the Neochord DS1000 System Versus Open Surgical Repair

NCT02803957
View directory record Official record
Conditions
Mitral Valve Insufficiency
Interventions
NeoChord DS1000, Surgical Mitral Valve Repair
Device
Lead sponsor
NeoChord
Industry
Eligibility
21 Years and older
Enrollment
585 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
14
States / cities
Sacramento, California • Stanford, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jul 22, 2026, 2:08 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Revised Hypertrophic Scars

NCT02246465
View directory record Official record
Conditions
Hypertrophic Scar
Interventions
RXI-109
Drug
Lead sponsor
RXi Pharmaceuticals, Corp.
Industry
Eligibility
21 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
5
States / cities
Beverly Hills, California • Lake Worth, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Jul 22, 2026, 2:08 PM EDT
Completed Not applicable Interventional Results available

Adductor Canal Catheter Effectiveness and Safety Study

NCT04639128
View directory record Official record
Conditions
Total Knee Replacement Surgery
Interventions
Adductor Canal Catheter
Device
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Leandro, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Jul 22, 2026, 2:08 PM EDT
Terminated Phase 2 Interventional

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

NCT00003715
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
BCG vaccine, autologous tumor cell vaccine, recombinant interferon alfa, chemotherapy, cyclophosphamide
Biological · Drug
Lead sponsor
AVAX Technologies
Industry
Eligibility
18 Years to 120 Years
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
17
States / cities
Rancho Mirage, California • New Haven, Connecticut • North Miami Beach, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Jul 22, 2026, 2:08 PM EDT
Completed Phase 1Phase 2 Interventional

Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer

NCT02422979
View directory record Official record
Conditions
Recurrent Head and Neck Cancer
Interventions
PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 160 mg/m^2, PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 320 mg/m^2, PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640 mg/m^2, PIT: 75 J/cm^2 for superficial lesions or 150 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2, PIT: 100 J/cm^2 for superficial lesions or 200 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2, PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2
Combination Product
Lead sponsor
Rakuten Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Jul 22, 2026, 2:08 PM EDT
Active, not recruiting Phase 3 Interventional

Thoracic Epidural Analgesia or Four-Quadrant Transversus Abdominus Plane Block in Reducing Pain in Patients Undergoing Liver Surgery

NCT03214510
View directory record Official record
Conditions
Liver and Intrahepatic Bile Duct Disorder
Interventions
Bupivacaine, Fentanyl, Hydromorphone Hydrochloride, Implanted Medical Device, Liposomal Bupivacaine, Questionnaire
Drug · Device · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 22, 2026, 2:08 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery

NCT04233073
View directory record Official record
Conditions
Surgery
Interventions
andexanet alfa
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 84 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
20
States / cities
Phoenix, Arizona • Tucson, Arizona • Long Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Jul 22, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery

NCT03011320
View directory record Official record
Conditions
Ovary Cancer
Interventions
EC1456, 99mTc-Etarfolatide
Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Concord, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Jul 22, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery

NCT02267226
View directory record Official record
Conditions
Congenital Fibrinogen Deficiency
Interventions
Octafibrin
Drug
Lead sponsor
Octapharma
Industry
Eligibility
12 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Jul 22, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

Immunogenicity and Safety Study of Topical Recombinant Thrombin in Surgical Hemostasis

NCT00491608
View directory record Official record
Conditions
Spinal Surgery, Vascular Surgery
Interventions
rThrombin
Biological
Lead sponsor
ZymoGenetics
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2012 · Synced Jul 22, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

NCT02872714
View directory record Official record
Conditions
UC (Urothelial Cancer)
Interventions
pemigatinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
34
States / cities
Tucson, Arizona • San Diego, California • San Francisco, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Jul 22, 2026, 2:08 PM EDT
Recruiting Phase 2 Interventional

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

NCT06797635
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer
Interventions
Patritumab deruxtecan, Pembrolizumab, Paclitaxel, Carboplatin, Doxorubicin hydrochloride, Epirubicin hydrochloride, Cyclophosphamide, Capecitabine, Olaparib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
8
States / cities
Santa Monica, California • Skokie, Illinois • Billings, Montana + 5 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 22, 2026, 2:08 PM EDT
Completed Not applicable Interventional Results available

Clinical Evaluation of Propel Nova Sinus Implant in Peripheral Sinus Ostia

NCT02228720
View directory record Official record
Conditions
Chronic Sinusitis
Interventions
Propel Nova Sinus Implant
Device
Lead sponsor
Intersect ENT
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Miami, Florida • Dublin, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Jul 22, 2026, 2:08 PM EDT
Suspended Phase 1Phase 2 Interventional

Propranolol Treatment for Postoperative Chylothorax

NCT06833320
View directory record Official record
Conditions
Postoperative Chylothorax, Congenital Heart Disease, Open Heart Surgery, Chylothorax
Interventions
Propranolol Hydrochloride, Placebo
Drug
Lead sponsor
June Wu
Other
Eligibility
7 Days to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 22, 2026, 2:08 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of the ELAD System (ELAD) to Treat Acute Liver Failure (ALF)

NCT01875874
View directory record Official record
Conditions
Acute Liver Failure, Fulminant Hepatic Failure, Primary Graft Non-Function, Surgically-Induced Liver Failure
Interventions
ELAD
Biological
Lead sponsor
Vital Therapies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
18
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Jul 22, 2026, 2:08 PM EDT
Not yet recruiting Phase 2 Interventional

The Effects of Timolol On Healing and Cosmesis of Mohs Scalp Wounds: An Open Label Trial

NCT07583862
View directory record Official record
Conditions
Surgical Wounds, Mohs Surgery
Interventions
Topical Timolol, Normal Saline
Drug
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jul 22, 2026, 2:08 PM EDT
Terminated Phase 3 Interventional Results available

Clinical Study to Evaluate the Effectiveness, Safety, and Tolerability of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects

NCT02687451
View directory record Official record
Conditions
Post-Operative Pain, Acute Pain
Interventions
Oxymorphone HCl, Placebo
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
0 Years to 2 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Durham, North Carolina • Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Jul 22, 2026, 2:08 PM EDT
Enrolling by invitation No phase listed Observational

Three Year Outcomes of Combined Hydrus Microstent With iTrack Canaloplasty

NCT07073937
View directory record Official record
Conditions
Glaucoma, Open Angle, MIGS, Minimally Invasive Glaucoma Surgery, Canaloplasty, Intraocular Pressure (IOP), Cataract Surgery, Surgical Technique, Minimally Invasive Surgical Technique, Glaucoma
Interventions
Retrospective chart review
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Jul 22, 2026, 2:08 PM EDT